Join us to Celebrate 10 Years of World ADC


Welcome Drink


Opening Remarks – Fiona Mistri from World ADC San Diego


Tumor-Targeted Immune-Stimulating Antibody Conjugates (ISAC): a New Class of Antibody Drug Conjugates

  • Introduce Bolt’s ISAC technology platform as the next evolution in immune-oncology and antibody drug conjugates
  • Describe key features of ISAC technology and mechanism of action

  • Demonstrate the promise of the ISAC platform and Bolt’s approach to develop this new class

Brian Safina, Vice President, Bolt Biotherapeutics


Sacituzumab: Mechanism of Action, Clinical Data & Updated Development Plan

  • Differentiated mechanism of action for an AD
  • Latest clinical data with SG
  • Updated Clinical Development plan

Trishna Goswami, Vice President, Clinical Development, Immunomedics


Antibody-drug Conjugates in the Clinic: Delivering Patient Benefit

  • Disease background and unmet medical needs of relapsed patients
  • Early trial results
  • Case vignettes

Adam Gibb, Clinical Research Fellow in Lymphoma, The Christie


My Journey from ADCT-301 to my Wedding Day

  • First Diagnosed - thoughts & feelings as a 25-year-old
  • What treatments I’ve had
  • Starting ADCT-301 & eventually having a transplant

Matthew Cragg was first diagnosed in Sept 2015 at the age of 25 with Hodgkins Lymphoma. Now he is 30, married and in remission thanks to ADCT-301.


Drinks & Networking


Closing Remarks

*You must be a registered attendee of World ADC San Diego to attend the ‘Celebrating 10 Years of World ADC’ Evening.

Complete this form to register for the ‘Celebrating 10 Years of World ADC’ evening.

Should you wish to attend this event please visit the registration page to choose how you would like to participate at World ADC San Diego